ArticleEuropean journal of medical research2025
Intelligent predictive risk assessment and management of sarcopenia in chronic disease patients using machine learning and a web-based tool.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Factors associated with sarcopenia in elderly patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Pooled it
- The risk prediction models for sarcopenia in older adults: a systematic review and critical appraisal.Frontiers in public health · 2026Pooled it
- Article
- An interpretable machine learning model predicts frailty risk in middle-aged and older adults with gastrointestinal disease: a longitudinal study.Scientific reports · 2026Article
- Machine learning evaluation of the discriminative ability of Castelli Risk Index-I and other non-traditional lipid indices for sarcopenia: a cross-sectional study based on CHARLS.Lipids in health and disease · 2026Article
- Enhancing sarcopenia screening in primary care: a machine learning approach using simple physical tests vs. SARC-F in 2,788 community-dwelling older adults.Frontiers in public health · 2026Article
- Integrated post-GWAS, single-cell, and functional analyses prioritizeFrontiers in immunology · 2026Article
- Machine learning-based diagnostic models for prevalent metabolic syndrome among patients with disuse muscle atrophy: a comparative study of seven algorithms.Frontiers in endocrinology · 2026Article
- Association between the ratio of uric acid to high-density lipoprotein cholesterol (UHR) and the abnormal risk of sarcopenia: Evidence from two large population-based surveys and interpretable machine learning-driven sarcopenia screening.Therapeutic advances in endocrinology and metabolism · 2026Article
- Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients.Frontiers in molecular biosciences · 2026Article
- Association of physical component score with high-risk lung nodules among Chinese Urban sanitation workers: a sex-specific analysis.Frontiers in public health · 2026Article
- Digital health technologies for the management of sarcopenia in patients receiving maintenance hemodialysis: a narrative review.Frontiers in nutrition · 2026Review
- Association between estimated glucose disposal rate and metabolic syndrome in older adults with sarcopenia.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with chronic diseases are at higher risk of sarcopenia, and precise prediction is essential for its prevention. This study aims to develop a risk scoring model using longitudinal data to predict the probability of sarcopenia in this population over next 3-5 years, thereby enabling early warning and intervention.
methodsUsing data from a nationwide survey initiated in 2011, we selected patient data records from wave 1 (2011-2012) and follow-up data from wave 3 (2015-2016) as the study cohort. Retrospective data collection included demographic information, health conditions, and biochemical markers. After excluding records with missing values, a total of 2891 adults with chronic conditions were enrolled. Sarcopenia was assessed based on the Asian Working Group for Sarcopenia (AWGS) 2019 guidelines. A generalized linear mixed model (GLMM) with random effects and diverse machine learning models were utilized to explore feature contributions to sarcopenia risk. The Recursive Feature Elimination (RFE) algorithm was employed to optimize the full Multilayer Perceptron (MLP) model and develop an online application tool.
resultsAmong total population, 580 (20.1%) individuals were diagnosed with sarcopenia in wave 1 (2011-2012), and 638 (22.1%) were diagnosed in wave 3 (2015-2016), while 2165 (74.9%) individuals were not diagnosed with sarcopenia across the study period. MLP model, performed better than other three classic machine learning models, demonstrated a ROC AUC of 0.912, a PR AUC of 0.401, a sensitivity of 0.875, a specificity of 0.844, a Kappa value of 0.376, and an F1 score of 0.44. According to MLP model-based SHapley Additive exPlanations (SHAP) scoring, weight, age, BMI, height, total cholesterol, PEF, and gender were identified as the most important features of chronic disease individuals for sarcopenia. Using the RFE algorithm, we selected six key variables-weight, age, BMI, height, total cholesterol, and gender-achieving an ROC AUC of about 0.9 for the online application tool.
conclusionWe developed an MLP machine learning model that incorporates only six easily accessible variables, enabling the prediction of sarcopenia risk in individuals with chronic diseases. Additionally, we created a practical online application tool to assist in decision-making and streamline clinical assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.